Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
{{output}}
Introduction: EGFR G724S has been described to mediate resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided compelling evidence that G724S retains sensitivity for af... ...
